In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Bio-Path Holdings (BPTH), with a price target of $10.00. The company’s shares closed last Wednesday at $6.29, close to its 52-week low of $2.92.
According to TipRanks.com, Chen is a top 25 analyst with an average return of 72.6% and a 61.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics.
Currently, the analyst consensus on Bio-Path Holdings is a Moderate Buy with an average price target of $11.50, a 69.1% upside from current levels. In a report released today, Roth Capital also initiated coverage with a Buy rating on the stock with a $13.00 price target.
See today’s analyst top recommended stocks >>
Based on Bio-Path Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $2.97 million. In comparison, last year the company had a GAAP net loss of $2.24 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
